Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Gemcitabine
100%
Single Institution
100%
Phase II Study
100%
Chemoradiation
100%
Pancreatic Adenocarcinoma
100%
Adjuvant Interferon
100%
Confidence Interval
75%
Interferon-α (IFN-α)
75%
Overall Survival
50%
Adjuvant Therapy
50%
5-fluorouracil (5-FU)
50%
Patient-completed
25%
Disease Progression
25%
Median Overall Survival
25%
Chemotherapy
25%
Disease-free Survival
25%
External Beam Irradiation
25%
Single Center
25%
Intravenous Infusion
25%
Patient Survival
25%
Phase II Trial
25%
Dose Adjustment
25%
Continuous Infusion
25%
Curative Resection
25%
Intravenous Bolus
25%
Cisplatin
25%
Single-arm Study
25%
Historical Controls
25%
Node-positive Disease
25%
Withdrawal of Consent
25%
Nursing and Health Professions
Chemoradiotherapy
100%
Pancreas Adenocarcinoma
100%
Interferon
100%
Gemcitabine
100%
Confidence Interval
60%
Overall Survival
60%
Adenocarcinoma
40%
Adjuvant Therapy
40%
Fluorouracil
40%
Pancreas
40%
Intravenous Drug Administration
20%
Continuous Infusion
20%
Disease Exacerbation
20%
Disease Free Survival
20%
Cisplatin
20%
External Beam Radiotherapy
20%
Diseases
20%
Consent
20%
Medicine and Dentistry
Interferon
100%
Chemoradiotherapy
100%
Gemcitabine
100%
Pancreas Adenocarcinoma
100%
Overall Survival
60%
Adenocarcinoma
40%
Adjuvant Therapy
40%
Fluorouracil
40%
Arm
20%
Disease Exacerbation
20%
External Beam Radiotherapy
20%
Intravenous Drug Administration
20%
Cisplatin
20%
Disease Free Survival
20%
Continuous Infusion
20%
Phase II Trials
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Interferon
100%
Gemcitabine
100%
Pancreas Adenocarcinoma
100%
Overall Survival
60%
Adenocarcinoma
40%
Fluorouracil
40%
Chemotherapy
20%
Disease Free Survival
20%
Disease Exacerbation
20%
Cisplatin
20%
Phase II Trials
20%
Diseases
20%